← Back to Search

Other

TL-925 Arm for Dry Eye Syndrome

Phase 2
Waitlist Available
Research Sponsored by Telios Pharma, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
A diagnosis of dry eye disease for at least 6 months
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to the end of day 29 (±2 days)
Awards & highlights

Study Summary

This trial will test a new eye drop to treat moderate-severe Dry Eye Disease in 100 people, with two phases of 2 wks screening/run-in and 4 wks double-masked treatment.

Eligible Conditions
  • Dry Eye Syndrome

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
You have been diagnosed with dry eye disease for at least 6 months.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to the end of day 29 (±2 days)
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to the end of day 29 (±2 days) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Adverse events during screening & treatment period
Secondary outcome measures
Change from baseline in corneal and conjunctival staining
Change from baseline in ocular discomfort
Change from baseline visual acuity

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: TL-925 ArmActive Control1 Intervention
TL-925 will be administered OU BID
Group II: Placebo ArmPlacebo Group1 Intervention
Placebo will be administered OU BID

Find a Location

Who is running the clinical trial?

Telios Pharma, Inc.Lead Sponsor
9 Previous Clinical Trials
1,300 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has the TL-925 Arm been given the blessing of regulatory authorities?

"As this is a Phase 2 clinical trial, we have assigned TL-925 Arm with an intermediate safety rating of 2. This reflects the presence of supporting data for its security and lack thereof regarding efficacy."

Answered by AI

What is the cap on participants for this clinical trial?

"Affirmative. According to publicly available data on clinicaltrials.gov, this ongoing medical study was launched on February 27th 2023 and has since been amended on March 9th of the same year. The research is actively seeking out 100 participants from 3 distinct sites."

Answered by AI

Does this experiment have any available openings for participants?

"Yes, the clinicaltrials.gov website indicates that this investigation is actively seeking out participants. This clinical trial was first published on February 27th 2023 and has been updated as recently as March 9th 2023. A total of one hundred individuals need to be recruited across three different medical centres."

Answered by AI
~51 spots leftby Mar 2025